{"classes":[{"categories":[{"measurements":[{"comment":"NA = Not estimable due to insufficient number of participants with events","groupId":"OG000","lowerLimit":"19.4","upperLimit":"NA","value":"33.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"86"}],"units":"Participants"}],"description":"Progression-free survival was defined as the time from the starting date of zanubrutinib to the date of first documentation of disease progression or death, whichever occurred first. Participants who did not have disease progression were censored at their last valid tumor assessment. A six-month progression-free survival rate was defined as no disease progression after treated with zanubrutinib for over six months (under control). The 95% confidence interval (CI) lower bound was 33.1 months while the upper bound could not be estimated.","dispersionType":"95% Confidence Interval","groups":[{"description":"Zanubrutinib (160 mg) administered BID until disease progression, unacceptable toxicity or death, withdrawal of consent, lost to follow up, or study termination by sponsor, which comes first.","id":"OG000","title":"Zanubrutinib"}],"paramType":"MEDIAN","populationDescription":"Safety Analysis Set: All participants who received any dose of study drug.","reportingStatus":"POSTED","timeFrame":"Up to 3 years and 6 months","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"months"}